|Bid||0.00 x 4000|
|Ask||0.00 x 900|
|Day's range||49.46 - 49.70|
|52-week range||41.03 - 58.37|
|PE ratio (TTM)||20.15|
|Forward dividend & yield||1.28 (2.63%)|
|1y target est||60.40|
A handful of the world’s biggest drugmakers are canceling or reducing planned price increases in the U.S., following a new California drug pricing transparency law and continued political pressure over pharmaceutical costs. The California law, which began to take effect earlier this year, requires drugmakers to give insurers, governments and drug purchasers advance notice of large price increases, as a way of publicly pressuring pharmaceutical companies to keep prices down. In the past three weeks, Novartis AG, Gilead Sciences Inc., Roche Holding AG and Novo Nordisk A/S sent notices to California health plans rescinding or reducing previously announced price hikes on at least 10 drugs.
In the first quarter, Novo Nordisk’s (NVO) Hemophilia segment generated net revenues of 2.5 billion Danish kroner compared to 2.58 billion Danish kroner in the first quarter of 2017, reflecting ~3.0% YoY (year-over-year) growth.
Novo Nordisk’s (NVO) Victoza generated revenues of 5.99 billion Danish kroner in the first quarter, compared to 5.75 billion Danish kroner in the first quarter of 2017, reflecting ~4.0% YoY (year-over-year) growth.
In the first quarter, Novo Nordisk’s (NVO) premix insulin generated net revenues of 2.64 billion Danish kroner compared to 2.86 billion Danish kroner in the first quarter of 2017, which reflected an ~8.0% YoY (year-over-year) decline.
Novo Nordisk’s (NVO) Tresiba reported revenues of 1.76 billion Danish kroner in the first quarter compared to 1.49 billion Danish kroner in the first quarter of 2017, which reflected ~18.0% YoY (year-over-year) growth.
In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial. This trial demonstrated that oral semaglutide significantly decreased the blood sugar levels in individuals with type 2 diabetes compared to placebo therapy.
Novo Nordisk (NVO) reported revenues of 26.9 billion Danish kroner in the first quarter, compared to 28.5 billion Danish kroner in the first quarter of 2017, which reflected an ~5.0% year-over-year (or YoY) decline.
Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study....
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Shares in Novo Nordisk (NOVOb.CO) opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets. Denmark's Novo Nordisk said in May that the new rules would cut its 2019 sales by 1-2 percent but kept its long-term operating growth forecast of 5 percent. According to Danish daily Borsen, the firm is now considering ditching the long-term target due to "uncertain and unpredictable markets".
In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.
Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
Obesity is a global epidemic. Nearly one-quarter (22%) of the people in the world will be obese by 2045, up from 14% in 2017, and one in eight will have type 2 diabetes, up from 9% in 2017, it concluded. Using a World Health Organization database and dividing each country’s population into age groups, the authors suggest that — in order to stabilize the rate of global diabetes at 10% — obesity rates must fall from the current level of 14% to 10% by 2045.
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.